Abstract
In this article the clinical experiences with the new nonsulphydryl angiotensin-converting enzyme inhibitor trandolapril are reviewed. The drug lowers blood pressure effectively in patients with mild-to-severe hypertension including elderly and obese patients. Distinguishing features of the compound are its long plasma half-life and high degree of lipophilicity. © 1993.
Original language | English |
---|---|
Pages (from-to) | 1542-1546 |
Number of pages | 5 |
Journal | American Heart Journal |
Volume | 125 |
Issue number | 5 PART 2 |
DOIs | |
Publication status | Published - 1993 |
Externally published | Yes |
Keywords
- Angiotensin-Converting Enzyme Inhibitors/*therapeutic use Clinical Trials as Topic Humans Hypertension/*drug therapy Indoles/*therapeutic use